We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PEDIATRIC DESIGNATION MAY DELAY GENERIC LAUNCH OF PARAPLATIN
PEDIATRIC DESIGNATION MAY DELAY GENERIC LAUNCH OF PARAPLATIN
April 6, 2004
In a move to block generic competition by an additional six months, Bristol-Myers Squibb (BMS) March 31 filed data with the FDA from two clinical studies involving the pediatric use of its profitable cancer drug Paraplatin (carboplatin).